Literature DB >> 26485842

AN INITIAL INDICATION OF PREDISPOSING RISK OF SCHISTOSOMA MANSONI INFECTION FOR HEPATOCELLULAR CARCINOMA.

Abd El Hamid A Sabry, Amany A Abd El-Aal, Naglaa Saad Mahmoud, Yossra Nabil, Inas Z Abdel Aziz.   

Abstract

Estimated 500,000 - 1 million cases of hepatocellular carcinoma (HCC) are reported to occur yearly worldwide, with a mean annual incidence of around 3 - 4% of global population. HCC is rapidly fatal in most patients; that makes its incidence and mortality rates almost equal. In the last 5-10 years there were many alarming reports of sharply increased incidence of HCC. In Egypt, HCC reported to account for about 4.7% of chronic liver disease (CLD) patients, which has tremendous impact on socio-economic development in the country. Available data suggests indirect evidence of an association between Schistosoma mansoni and hepatocellular carcinoma, possibly through potentiation of hepatitis infections. The present study was conducted case control analysis of 60 HCC patients. Chronic schistosomiasis cases were confirmed by finding Anti-Schistosoma mansoni antibodies IgG by ELISA. Hepatitis C viral infection was proved by detection of viral load by quantitative Real time PCR. Among the study group 56.6% (34/60) were dweller in rural in Al-Fayoum governorate. Within hepatocellular carcinoma cases 26.7% (16/60) and 33.3% (20/60) suffered mono chronic schistosomiasis and mono hepatitis C (HCV) infections respectively, with no statistically significant differences (p=0.37), indicating comparable risk value of both infections in predisposing directly to HCC. Additionally; frequency of HCC patients with assumed potentiated HCV infection by chronic Schistosoma mansoni 6.7% (4/60) were statistically significant (p<0.05) less among total HCC patients included in this study, when compared to HCC patients preceded by either pure chronic schistosomiasis 26.7% (16/60) or pure HCV infection 33.3% (20/60). Our present study is one of few, addressing the possibility of direct relation between S. mansoni & hepatic carcinoma, concluding an initial indication of equal risk value of both human chronic S. mansoni infection and hepatitis C viral infections in precipitating hepatocellular carcinoma among Egyptian patients.

Entities:  

Mesh:

Year:  2015        PMID: 26485842     DOI: 10.12816/0017568

Source DB:  PubMed          Journal:  J Egypt Soc Parasitol        ISSN: 1110-0583


  4 in total

1.  Targeting AMPK, mTOR and β-Catenin by Combined Metformin and Aspirin Therapy in HCC: An Appraisal in Egyptian HCC Patients.

Authors:  Doaa Ali Abdelmonsif; Ahmed S Sultan; Wessam F El-Hadidy; Dina Mohamed Abdallah
Journal:  Mol Diagn Ther       Date:  2018-02       Impact factor: 4.074

2.  Schistosoma mansoni infection and the occurrence, characteristics, and survival of patients with hepatocellular carcinoma: an observational study over a decade.

Authors:  Hend Ibrahim Shousha; Ashraf Omar Abdelaziz; Mohamed Mahmoud Nabeel; Dalia Abdelhamid Omran; Ahmed Hosni Abdelmaksoud; Tamer Mahmoud Elbaz; Ayman Salah; Shady Tarek ElGhazaly Harb; Karim Adel Hosny; Ayman Osman; Mira Atef; Abdelazez Gaber; Naglaa Ali Zayed; Ayman Abdelhady Yosry; Rania Leithy
Journal:  Pathog Glob Health       Date:  2021-09-08       Impact factor: 3.735

3.  Liver Disease Outcomes after Sustained Virological Response in Patients with Chronic Hepatitis C Infection Treated with Generic Direct-Acting Antivirals.

Authors:  Ekram W Abd El-Wahab; Waleed M Abd Elgawad; Mohamed S Abdelaziz; Ashraf I Mikheal; Hanan Z Shatat
Journal:  Am J Trop Med Hyg       Date:  2022-02-28       Impact factor: 3.707

4.  Schistosomal liver fibrosis and hepatocellular carcinoma - case series of patients submitted to liver transplantation.

Authors:  Norma Arteiro Filgueira; Camilla Maria de Alencar Saraiva; Norma Thomé Jucá; Matheus Filgueira Bezerra; Claudio Moura Lacerda
Journal:  Braz J Infect Dis       Date:  2018-07-12       Impact factor: 3.257

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.